Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis

Research output: Contribution to journalArticlepeer-review

Abstract

© 2014 Elsevier Ltd. Recombinant virus mediated gene therapy of Leber's Congenital Amaurosis has provided a wide range of data on the utility of gene replacement therapy for recessive diseases. Studies to date demonstrate that gene therapy in the eye is safe and can result in long-term recovery of visual function, but they also highlight that further research is required to identify optimum intervention time-points, target populations and the compatibility of associate therapies. This article is part of a directed issue entitled: Regenerative Medicine: the challenge of translation.
Original languageEnglish
Pages (from-to)153-157
JournalInternational Journal of Biochemistry and Cell Biology
Volume56
DOIs
Publication statusPublished - 2014

Fingerprint

Dive into the research topics of 'Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis'. Together they form a unique fingerprint.

Cite this